HK1211475A1 - Combination therapy - Google Patents

Combination therapy Download PDF

Info

Publication number
HK1211475A1
HK1211475A1 HK15112282.5A HK15112282A HK1211475A1 HK 1211475 A1 HK1211475 A1 HK 1211475A1 HK 15112282 A HK15112282 A HK 15112282A HK 1211475 A1 HK1211475 A1 HK 1211475A1
Authority
HK
Hong Kong
Prior art keywords
combination therapy
agent
pharmaceutically acceptable
acceptable salt
inhibitor
Prior art date
Application number
HK15112282.5A
Other languages
English (en)
Chinese (zh)
Inventor
Shivang Doshi
Sunkyu Kim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1211475A1 publication Critical patent/HK1211475A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15112282.5A 2012-11-28 2013-11-25 Combination therapy HK1211475A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730661P 2012-11-28 2012-11-28
US61/730,661 2012-11-28
PCT/US2013/071659 WO2014085318A1 (en) 2012-11-28 2013-11-25 Combination therapy

Publications (1)

Publication Number Publication Date
HK1211475A1 true HK1211475A1 (en) 2016-05-27

Family

ID=49753505

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112282.5A HK1211475A1 (en) 2012-11-28 2013-11-25 Combination therapy

Country Status (12)

Country Link
US (1) US9408847B2 (enExample)
EP (1) EP2925365A1 (enExample)
JP (2) JP2016501221A (enExample)
KR (1) KR20150089053A (enExample)
CN (1) CN104812414A (enExample)
AU (4) AU2013352406A1 (enExample)
BR (1) BR112015012197A8 (enExample)
CA (1) CA2891938A1 (enExample)
HK (1) HK1211475A1 (enExample)
MX (1) MX2015006809A (enExample)
RU (1) RU2015125307A (enExample)
WO (1) WO2014085318A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103635189B (zh) * 2011-07-01 2016-05-04 诺华股份有限公司 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗
RS59790B1 (sr) 2013-03-15 2020-02-28 G1 Therapeutics Inc Privremena zaštita normalnih ćelija tokom hemoterapije
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CA2936962C (en) 2014-03-14 2024-03-05 Novartis Ag Antibody molecules to lag-3 and uses thereof
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
SMT202300072T1 (it) 2014-03-28 2023-05-12 Univ Duke Cancro della mammella mediante l'utilizzo di modulatori selettivi del recetiore degli estrogeni
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CA2964367C (en) 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
HK1247089A1 (zh) 2015-03-10 2018-09-21 Aduro Biotech, Inc. 用於活化“干扰素基因刺激物”依赖性信号传导的组合物和方法
CN106336412A (zh) * 2015-07-10 2017-01-18 南开大学 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
EP3156406A1 (en) * 2015-10-14 2017-04-19 ratiopharm GmbH Crystalline forms of ribociclib free base
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
RU2022108295A (ru) * 2016-06-22 2022-04-06 Эллипсес Фарма Лтд Способы лечения ar+ рака молочной железы
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018081211A1 (en) * 2016-10-26 2018-05-03 Li George Y Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
US11083722B2 (en) 2017-03-16 2021-08-10 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
MY204117A (en) 2017-06-22 2024-08-08 Novartis Ag Antibody molecules to cd73 and uses thereof
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
TWI750539B (zh) * 2018-11-23 2021-12-21 大陸商蘇州亞盛藥業有限公司 新穎藥物組成物及其用途
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012011912A (es) * 2010-04-13 2012-11-16 Novartis Ag Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclia (cdk4/6) y un inhibidor de mtor para tratar cancer.

Also Published As

Publication number Publication date
AU2013352406A1 (en) 2015-06-04
EP2925365A1 (en) 2015-10-07
AU2019200881A1 (en) 2019-02-28
CA2891938A1 (en) 2014-06-05
CN104812414A (zh) 2015-07-29
JP2016501221A (ja) 2016-01-18
WO2014085318A1 (en) 2014-06-05
MX2015006809A (es) 2015-08-06
JP2019031500A (ja) 2019-02-28
BR112015012197A8 (pt) 2019-10-01
BR112015012197A2 (pt) 2017-07-11
AU2016262781A1 (en) 2016-12-15
AU2018200323A1 (en) 2018-02-01
KR20150089053A (ko) 2015-08-04
RU2015125307A (ru) 2017-01-10
US9408847B2 (en) 2016-08-09
US20150306104A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
HK1211475A1 (en) Combination therapy
WO2013188783A8 (en) Deuterated derivatives of ruxolitinib
HK1216176A1 (zh) 用於治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
MX378263B (es) Terapia de combinación para el tratamiento del cáncer.
WO2015021358A3 (en) Compounds and methods for inhibiting phosphate transport
IL239639A0 (en) A modified spiropyrido {1,2-a} pyrazine derivative and its medicinal use as an HIV integrase inhibitor
HK1210775A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
WO2013003669A3 (en) Compositions, methods of use, and methods of treatment
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
HK1206726A1 (en) Imidazotriazinone compounds
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
HK1223304A1 (zh) 包含二甲双胍和二氢槲皮素的药物组合及其用於治疗癌症的用途
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
HK1217092A1 (zh) 治疗性化合物及其用途
WO2014160281A3 (en) Method of enhancing delivery of therapeutic compounds to the eye
WO2012118308A3 (ko) 피라졸 유도체를 포함하는 심혈관 질환 예방 및 치료용 조성물.
WO2013117744A3 (en) Methods of treating fibrosis
EP3061455A4 (en) Therapeutic agent for ocular disease or prophylactic agent for ocular disease
EP2987786A4 (en) AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
CA2863409A1 (en) N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
HK1216721A1 (zh) 治疗肝脏疾病或病状的用途和方法
WO2015082590A3 (en) Bis-mmf derivatives